Price T Rowe Associates Inc. MD boosted its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) by 6.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,058,615 shares of the company's stock after acquiring an additional 188,820 shares during the quarter. Price T Rowe Associates Inc. MD owned 2.13% of Denali Therapeutics worth $62,335,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. Rhumbline Advisers boosted its position in shares of Denali Therapeutics by 0.3% in the fourth quarter. Rhumbline Advisers now owns 190,390 shares of the company's stock worth $3,880,000 after purchasing an additional 497 shares during the period. PNC Financial Services Group Inc. boosted its holdings in Denali Therapeutics by 30.5% in the 4th quarter. PNC Financial Services Group Inc. now owns 3,790 shares of the company's stock worth $77,000 after buying an additional 885 shares during the period. Sterling Capital Management LLC increased its stake in Denali Therapeutics by 589.9% in the 4th quarter. Sterling Capital Management LLC now owns 1,773 shares of the company's stock worth $36,000 after buying an additional 1,516 shares in the last quarter. E Fund Management Co. Ltd. raised its holdings in Denali Therapeutics by 32.2% during the fourth quarter. E Fund Management Co. Ltd. now owns 9,997 shares of the company's stock valued at $204,000 after acquiring an additional 2,436 shares during the period. Finally, KBC Group NV lifted its position in shares of Denali Therapeutics by 75.8% in the fourth quarter. KBC Group NV now owns 6,334 shares of the company's stock valued at $129,000 after acquiring an additional 2,731 shares in the last quarter. Institutional investors own 92.92% of the company's stock.
Wall Street Analysts Forecast Growth
DNLI has been the subject of several research analyst reports. William Blair upgraded Denali Therapeutics to a "strong-buy" rating in a research report on Thursday, April 24th. Baird R W raised shares of Denali Therapeutics to a "strong-buy" rating in a report on Tuesday, January 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Denali Therapeutics in a report on Tuesday, February 11th. They issued a "buy" rating and a $31.00 target price on the stock. Morgan Stanley started coverage on shares of Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 target price for the company. Finally, Oppenheimer decreased their price target on shares of Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a research note on Monday, March 3rd. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $37.57.
View Our Latest Stock Analysis on DNLI
Denali Therapeutics Stock Up 2.4 %
Shares of DNLI stock traded up $0.38 during mid-day trading on Friday, hitting $16.44. 1,118,564 shares of the stock were exchanged, compared to its average volume of 1,087,313. The company has a market cap of $2.39 billion, a PE ratio of -5.96 and a beta of 1.49. Denali Therapeutics Inc. has a 52-week low of $10.57 and a 52-week high of $33.33. The firm has a fifty day moving average of $14.51 and a 200 day moving average of $20.41.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. Equities analysts predict that Denali Therapeutics Inc. will post -2.71 EPS for the current year.
Denali Therapeutics Profile
(
Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More
Before you consider Denali Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Denali Therapeutics wasn't on the list.
While Denali Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
